Commercial Credit Report for Kohjin Bio Co Ltd

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for Kohjin Bio Co Ltd is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

	Kohjin Bio Co Ltd
5-1-3, Chiyoda
Phone: +81 492843781p:+81 492843781	SAKADO-SHI, STM 350-0214 Japan	Ticker: 177A177A

Business Summary

Kohjin Bio Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of bacterial testing media, in vitro diagnostic drugs, cell culture media, as well as contract cell processing. The Company operates through three segments. The Tissue Culture business segment develops, manufactures, and sells tissue culture media, including serum-free media used for research purposes in regenerative medicine and immunotherapy. The Microbiology business segment develops, manufactures, and sells a wide variety of microorganism detection media used for pathogen testing in the clinical and food fields, and quality testing in various fields such as pharmaceuticals and cosmetics. The Cell Processing business segment conducts cell processing operations under contract from medical institutions at facilities that have obtained permission to manufacture specified cell products based on the Regenerative Medicine Safety Act.

(Source: N-30D)

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	Moody's Rating	Fitch Rating	DBRS Rating
Yes	Yes	-	-	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
12/31/2023	3/31/2023	-	-	-	-	-

Industries

SIC Code	Description
2835	In vitro and in vivo diagnostic substances
2834	Pharmaceutical preparations
2836	Biological products, except diagnostic substances
5122	Drugs, drug proprietaries, and druggists' sundries

General Information

Number of Employees:	157	(As of 2/29/2024)
Outstanding Shares:	5,015,000	(As of 4/25/2024)
Stock Exchange:	TYO
Fax Number:	+81 492844784

SITE MAP | ABOUT US | DIRECTORY | STOCK QUOTE: CRMZ | SIGN IN